Propanc Biopharma (PPCB) Registration filing summary

Company overview and business model

• Focuses on developing novel cancer treatments targeting pancreatic, ovarian, and colorectal cancers using a proprietary proenzyme therapy (PRP) designed to prevent recurrence and metastasis by targeting cancer stem cells.

• Lead product PRP is in preclinical development, with plans to initiate a Phase Ib first-in-human study in advanced solid tumor patients, subject to sufficient financing.

• Holds an extensive intellectual property portfolio with 84 granted or allowed patents and 6 pending applications in key global jurisdictions.

• Operates primarily from Australia, with research collaborations in Europe and a commercialization agreement with the University of Bath, UK.

Financial performance and metrics

• No revenue-generating operations to date; all activities are focused on R&D and preparation for clinical trials.

• Reported net loss of $1.82 million for the fiscal year ended June 30, 2024, and $784,493 for the six months ended December 31, 2024.

• Accumulated deficit of $67.5 million as of December 31, 2024; working capital deficit of $4.1 million.

• Cash balance of $14,633 as of December 31, 2024; operations funded primarily through equity and convertible debt financings.

• Substantial doubt exists regarding ability to continue as a going concern without additional capital.

Use of proceeds and capital allocation

• Estimated net proceeds of $6.9 million from the IPO (or $7.94 million if over-allotment is exercised), primarily allocated to working capital and general corporate purposes.

• Management retains broad discretion over allocation of proceeds; funds expected to support operations for 12–18 months.